Unity Biotechnology (STU:9U90) Additional Paid-In Capital : €473.03 Mil(As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Unity Biotechnology Additional Paid-In Capital?

Unity Biotechnology's quarterly additional paid-in capital declined from Sep. 2023 (€500.89 Mil) to Dec. 2023 (€470.21 Mil) but then increased from Dec. 2023 (€470.21 Mil) to Mar. 2024 (€473.03 Mil).

Unity Biotechnology's annual additional paid-in capital increased from Dec. 2021 (€406.78 Mil) to Dec. 2022 (€472.78 Mil) but then declined from Dec. 2022 (€472.78 Mil) to Dec. 2023 (€470.21 Mil).

Unity Biotechnology Additional Paid-In Capital Historical Data

The historical data trend for Unity Biotechnology's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Unity Biotechnology Additional Paid-In Capital Chart

Unity Biotechnology Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

330.03

347.20

406.78

472.78

470.21

Unity Biotechnology Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															494.64	491.56	500.89	470.21	473.03

Unity Biotechnology Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Unity Biotechnology Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Unity Biotechnology's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Unity Biotechnology (STU:9U90) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Unity Biotechnology Inc (STU:9U90) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

UBX:USA 9U90:Germany

Address

285 East Grand Avenue, South San Francisco, CA, USA, 94080

Website

https://www.unitybiotechnology.com

Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases.

Unity Biotechnology (STU:9U90) Headlines

No Headlines